「161Tb」Tb-DOTATATE 作为神经母细胞瘤潜在治疗选择
该临床前研究将 DOTATATE 用铽-161 标记,在体外和神经母细胞瘤模型中评估「161Tb」Tb-DOTATATE 的靶向性与疗效。结果显示其 SSTR2 特异性结合、体内分布和肿瘤摄取与「177Lu」Lu-DOTATATE 相当,且在可比活度下早期肿瘤控制更强,疗效呈活度依赖,未观察到治疗相关毒性。
要点
- 「161Tb」Tb-DOTATATE 标记产率高且稳定,体外显示 SSTR2 特异性结合。
- 体内分布和肿瘤摄取与「177Lu」Lu-DOTATATE 相当。
- 可比活度下早期肿瘤控制优于「177Lu」Lu-DOTATATE(第9天 p<0.01)。
核心结论
- 「161Tb」Tb-DOTATATE 在神经母细胞瘤临床前模型中靶向性良好、疗效呈活度依赖且未检测到毒性。
- 结果支持将其作为「177Lu」Lu-DOTATATE 的补充,尤其针对微小残留病和微转移,值得进一步临床前与临床评估。
研究设计与样本
- 临床前研究:将 DOTATATE 用铽-161 标记,进行体外结合实验与体内生物分布及肿瘤摄取评估。
- 在神经母细胞瘤模型中比较不同活度「161Tb」Tb-DOTATATE 与「177Lu」Lu-DOTATATE 的疗效与生存。
主要发现
- 「161Tb」Tb-DOTATATE 在体外显示明确的 SSTR2 特异性结合。
- 体内生物分布和肿瘤摄取与「177Lu」Lu-DOTATATE 相当。
- 治疗以活度依赖方式抑制肿瘤生长,可比活度下第9天早期肿瘤控制强于「177Lu」Lu-DOTATATE(**p < 0.01)。
- 肿瘤倍增时间在 6 MBq「161Tb」Tb-DOTATATE 组最长(29 天 vs 对照组 18 天)。
- 3 MBq「161Tb」Tb-DOTATATE 组与 4 MBq「177Lu」Lu-DOTATATE 组倍增时间相近(21 天 vs 22 天)。
关键数值与推荐
- 6 MBq「161Tb」Tb-DOTATATE 组中位生存改善最大(50% 增加)。
- 4 MBq「161Tb」Tb-DOTATATE 组中位生存增加 36%。
- 3 MBq「161Tb」Tb-DOTATATE 与 4 MBq「177Lu」Lu-DOTATATE 组中位生存改善较温和(23%)。
- 所有治疗方案耐受良好,未观察到治疗相关毒性征象。
临床怎么用
- 目前仅为临床前证据,尚不能直接用于临床决策。
- 提示「161Tb」Tb-DOTATATE 可能作为「177Lu」Lu-DOTATATE 的补充,用于 SSTR2 表达神经母细胞瘤的微小残留病和微转移。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neuroblastoma is an aggressive paediatric malignancy with poor outcomes in high-risk patients despite multimodal therapy. [177Lu]Lu-DOTATATE, targeting somatostatin receptor 2 (SSTR2), is under clinical investigation for neuroblastoma. Terbium-161 (161Tb) shares chemical characteristics and a similar half-life with lutetium-177 (177Lu) but offers advantages through its higher emission of Auger and conversion electrons, which may enhance therapeutic efficacy especially for micrometastases and recurrent disease. This study investigates [161Tb]Tb-DOTATATE as a potential complement for treatment of SSTR2-expressing neuroblastoma. RESULTS: DOTATATE was successfully radiolabelled with 161Tb, achieving high radiochemical yield and stability. [161Tb]Tb-DOTATATE demonstrated clear SSTR2-specific binding in vitro, as well as biodistribution and tumour uptake comparable to [177Lu]Lu-DOTATATE in vivo. Treatment with [161Tb]Tb-DOTATATE reduced tumour growth in an activity-dependent manner, and demonstrated stronger early tumour control compared to [177Lu]Lu-DOTATATE at comparable administered activities (**p < 0.01 at day 9). Tumour doubling times were longest in the 6 MBq [161Tb]Tb-DOTATATE group (29 vs. 18 days in controls), while the 3 MBq [161Tb]Tb-DOTATATE group showed similar doubling times to 4 MBq [177Lu]Lu-DOTATATE (21 vs. 22 days). This was also reflected in survival, where 6 MBq [161Tb]Tb-DOTATATE achieved the greatest effect (50% increase in median survival), followed by 4 MBq [161Tb]Tb-DOTATATE (36%), while 3 MBq [161Tb]Tb-DOTATATE and 4 MBq [177Lu]Lu-DOTATATE showed more modest improvements (23%). All treatment regimens were well tolerated, and no signs of treatment-related toxicity were observed. CONCLUSION: [161Tb]Tb-DOTATATE demonstrates favourable targeting properties and activity-dependent therapeutic efficacy in preclinical neuroblastoma models without detectable toxicity. These findings encourage us to explore its potential as a complement to [177Lu]Lu-DOTATATE, particularly for targeting minimal residual disease and micrometastases, and warrant further preclinical and clinical evaluation.
引用
- Chopra S, Xu T, Berglund H, et al. [161Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma. EJNMMI Res. 2026. PMID: 42518020. doi:10.1186/s13550-026-01487-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。